Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
For now, the group is sticking with what it knows ahead of a big year in lymphoma.
Despite magrolimab’s latest flop, efforts to target CD47 continue.
The latest clinical study listings reveal KRAS-targeting projects, ADCs and others starting phase 1.
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
Pelabresib's partial win at ASH was enough to persuade Novartis to pull the acquisition trigger.
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.